<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383211</url>
  </required_header>
  <id_info>
    <org_study_id>GWMDA2017</org_study_id>
    <nct_id>NCT03383211</nct_id>
  </id_info>
  <brief_title>Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers</brief_title>
  <acronym>IMMUNEO</acronym>
  <official_title>Transcriptomic Profile of the Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitatea de Stat de Medicina si Farmacie Nicolae Testemi≈£anu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DC-Center for Aids Research (DC-CFAR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SeqLL, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maternal infections affect the basal immune status of neonates. One of the possible mechanism&#xD;
      is the fetomaternal microchimerism, in which some cells and active substances are exchanged&#xD;
      bi-directionally between maternal and fetal circulation through placenta. Even in the absence&#xD;
      of a direct (vertical) transmission of pathogens to fetuses, certain infections make the&#xD;
      neonates more prone to allergies and some adverse events of early vaccinations. We postulate&#xD;
      that the basal immune status of neonates born to HIV and LTBI infected mothers is primed by&#xD;
      gestational exposure to immunological active molecules, which could results in an altered&#xD;
      response to early BCG vaccination. Transcripts expression identified by RNA sequencing are&#xD;
      compared between sets of mother-child and their respective umbilical cord blood, and between&#xD;
      groups of infected and non-infected pairs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is comparing the transcriptomic profiles of maternal peripheral blood with those of&#xD;
      the corresponding umbilical cord blood and neonatal peripheral blood pre- and post-BCG&#xD;
      vaccination.&#xD;
&#xD;
      For RNA sequencing, the samples are collected in Tempus RNA Blood tubes at 5 time-points&#xD;
      (TP): maternal peripheral blood at the time of initial diagnosis with HIV (first OBGYN&#xD;
      consultation @ 12-16 weeks of pregnancy - TP1); repeated HIV test in 3rd trimester of&#xD;
      pregnancy (34-36 weeks- TP2); umbilical cord blood (after delivery and ligation- TP3);&#xD;
      neonates (24 hours after birth and after HBV vaccination, prior to BCG vaccination- TP4); and&#xD;
      neonates (7 days after BCG vaccination- TP5).&#xD;
&#xD;
      As an indicator of the inflammatory status, the peripheral blood samples collected at the&#xD;
      same TP are stained for serological markers of inflammation, exhaustion, maturation and&#xD;
      activation.&#xD;
&#xD;
      An advanced bioinformatics analysis examines the immune-associated transcripts in RNAseq&#xD;
      samples to assess the V(D)J recombination of T-cell and B-cell receptors along with&#xD;
      immune-associated SNPs.&#xD;
&#xD;
      The main goal of the study is to identify in umbilical cord blood the genomic biomarkers of&#xD;
      the neonatal basal immune status for guiding an optimal BCG immunization protocol for such&#xD;
      neonates and to avoid potential adverse events after vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2017</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in immune-associated transcripts</measure>
    <time_frame>Collection of samples 7-days after BCG vaccination</time_frame>
    <description>Identification of transcripts that are differential expressed between groups</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">125</enrollment>
  <condition>HIV Infections</condition>
  <condition>Neonatal Infection</condition>
  <condition>LTBI - Latent Tuberculosis Infection</condition>
  <condition>Immune Tolerance</condition>
  <arm_group>
    <arm_group_label>HIV+</arm_group_label>
    <description>Pregnant women diagnosed with HIV infection during pregnancy. No intervention beyond the standard care provided for such cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTBI</arm_group_label>
    <description>Pregnant women diagnosed with Latent form of TB infection (LTBI). No intervention beyond the standard of care provided for such cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HV+/LTBI</arm_group_label>
    <description>Pregnant women diagnosed with HIV and LTBI co-infection. No intervention beyond the standard of care provided for such cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>Healthy pregnant women without HIV or LTBI. No intervention beyond the standard of care provided for such cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RNAseq</intervention_name>
    <description>Transcriptome profiling of peripheral blood using RNA sequencing technology</description>
    <arm_group_label>HIV+</arm_group_label>
    <arm_group_label>HV+/LTBI</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>LTBI</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA isolated from peripheral blood.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women, 18-45 years old who consented for participation in the study. All women are&#xD;
        managed by the local national healthcare system without any interventions from the research&#xD;
        team. The collection of samples is performed by the local trained medical personnel, and&#xD;
        the samples are processed in a research laboratory.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Pregnant women, 18-45 years old, capable of reading and understanding the informed consent&#xD;
        and the purpose of the study The newborns of the enrolled pregnant women. Women of&#xD;
        reproductive age with or without HIV and LTBI infections&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnant women younger than 18 years or older than 45 years of age Pregnant women and&#xD;
        infants with known genetic abnormalities, including primary immunodeficiencies; or&#xD;
        receiving immunosuppressive therapy; Infants infected in utero, perinatally, or neonatally&#xD;
        with hepatitis B virus, Treponema pallidum (syphilis), Toxoplasma gondii, rubella virus,&#xD;
        cytomegalovirus, or herpes simplex virus.&#xD;
&#xD;
        Pregnant women with known history of alcohol or drug abuse, cancer diagnosis and treatment&#xD;
        with chemotherapeutic agents, radiation.&#xD;
&#xD;
        Pregnant women with history of organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women or women of the reproductive age</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Toma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Municipal Hospital No. 1</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Mother and Child Health</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Moldova, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Ian Toma, MD, PhD</investigator_full_name>
    <investigator_title>Associate Research Professor</investigator_title>
  </responsible_party>
  <keyword>RNAseq</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <keyword>Transcriptome</keyword>
  <keyword>Peripheral blood transcripts</keyword>
  <keyword>Tempus Blood RNA Tubes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Genomic data will be submitted to the NCBI SRA archive</ipd_description>
    <ipd_time_frame>Upon completion of analysis</ipd_time_frame>
    <ipd_access_criteria>NCBI standard access criteria</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

